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A 5.8 Mb interstitial deletion on
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Abstract
Background: Deletions of the long arm of chromosome X in males are a rare cause of X-linked intellectual
disability. Here we describe a patient with an interstitial deletion of the Xq21.1 chromosome.
Case presentation: In a 15 year boy, showing intellectual disability, short stature, hearing loss and dysmorphic
facial features, a deletion at Xq21.1 was identified by array-CGH. This maternally inherited 5.8 Mb rearrangement
encompasses 14 genes, including BRWD3 (involved in X-linked intellectual disability), TBX22 (a gene whose
alterations have been related to the presence of cleft palate), POU3F4 (mutated in X-linked deafness) and ITM2A
(a gene involved in cartilage development).
Conclusion: Correlation between the clinical findings and the function of gene mapping within the deleted region
confirms the causative role of this microrearrangement in our patient and provides new insight into a gene
possibly involved in short stature.
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Background
Cytogenetically detectable chromosomal deletions in-
volving chromosome X are rare in males due to the in-
compatibility with life of nullisomy for large portions of
this chromosome. In particular, deletions at Xq21 are
poorly described in the literature and only a few cases
are reported of male patients with complex phenotypes
including neurosensorial deafness, choroideremia, intel-
lectual disability and dysmorphisms [1]. About 50 % of
the carrier females display almost or completely skewed
X inactivation, silencing the abnormal X resulting in a
relatively benign phenotype [2]. The development of
high resolution genomic arrays has made it possible to
increase the imbalance detection rate with the identifica-
tion of cryptic small rearrangements on the X chromo-
some, some of these containing only a few genes or even
just a single gene [3, 4]. However, despite the improve-
ment of the analysis resolution, rearrangements at Xq21
are still rarely reported.
Here we describe a male patient with an interstitial dele-
tion of the Xq21.1 chromosome, determined through array
comparative genome hybridization (aCGH). We sought to
explain the clinical outcome, according to genotype-
phenotype correlation, focusing on the genes possibly
involved in the clinical phenotype including intellectual im-
pairment, hearing loss, cleft-palate and short stature.
Case presentation
The patient was born at the 41st week of gestation by
caesarean section due to fetal macrosomia. The birth
weight was 4,530 g (>97° percentile), birth length 54 cm
(90–97° percentile), and head circumference 40 cm (>97°
percentile). Apgar scores were 9 and 10 at 1 and 5 mi-
nutes, respectively. The propositus was the only child of
non-consanguineous Italian parents. The father was 36
and the mother was 28 years old. At birth, the patient
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showed cleft palate (plastic surgery of the hard palate was
performed at the 5th month of life), hip dysplasia (corrected
with retractor), right blepharoptosis (surgically corrected at
7 years of age) and dysmorphic face. At the fourth month
of age, the parents noted the presence of severe head and
limb hypotonia and a delayed psychomotor development.
At 18 months, bilateral sensorineural hearing loss was diag-
nosed and a bilateral hearing aid was implanted.
The standard cytogenetic analysis revealed a normal
male karyotype (46,XY). The patient proved negative for
chromosome 22.11.2 deletion syndrome and fragile-X
syndrome analysis. The family history was negative for
intellectual disability.
Neurological examinations were performed, including
a brain MRI at the age of 1 year with evidence of peri-
natal outcome suffering of the white matter, thinning of
the corpus callosum and mild ventricular asymmetry. At
8 years of age, the brain MRI was repeated and showed
the presence of mild ectasia of the perivascular spaces,
soft signal hyperintensity of the periventricular white
matter in the occipital region bilaterally as incomplete
myelination.
At 3 years of age, because of short stature, a growth
hormone (GH) stimulation test with arginine (GH peak:
5 ng/ml; n.v. > 10 ng/ml) and with glucagon (GH peak:
2.1 ng/ml; n.v. > 10 ng/ml) were performed and led to a
diagnosis of complete growth hormone deficiency
(GHD). GH replacement therapy was therefore started
at the age of 4 years and stopped at the age of 9 years,
for poor growth response. The patient did not return for
further medical examination until the age of 15 years,
when he was reassessed at our center for growth arrest
associated with suspected hypogonadism (gonadal volume
2 cc bilaterally). His height was 151 cm (−2.23 SDS), BMI
26.97 kg/m2 (1.47 SDS). The gonadotropin evaluation tests
performed with luteinizing-hormone-releasing hormone
(LHRH) revealed deficit of luteinizing hormone (LH)
and follicle-stimulating hormone (FSH) with a LH peak
of 4.1 mU/ml (prepubertal value) and FSH peak of
7.3 mU/ml (prepubertal value). The stimulation test
with growth-hormone-releasing hormone (GHRH) and
arginine confirmed the severe GHD (GH peak: 0.1 ng/ml;
n.v. > 19 ng/ml). Insulin-like growth factor (IGF-1) was
below the normal range (<25.0 ng/ml; −7.81 SDS). Ad-
renal, thyroid, liver and kidney function showed normal
range values. The ECG and the cardiological examin-
ation were normal. A delayed bone age of 2 years com-
pared with chronological age was detected. A pituitary
MRI was also performed and showed a normal morph-
ology of the adenohypophysis, smaller than normal for
the age without significant alterations in signal intensity
before, during and after the administration of contrast
medium. The patient therefore restarted GH replace-
ment therapy.
For the psychomotor retardation with hyperactivity,
the child attends psychomotor and speech therapy regu-
larly and he is currently being treated with Levomepro-
mazine (75 mg/day) and Promazine (50 gtt/day). The
boy has a poor ability to tolerate frustration and there
have been some episodes of verbal aggression against its
peers. A neuropsychiatric test (Wisc IV test) showed an
intellectual disability with an IQ < 70.
Concerning the morphological aspect (Fig. 1), the pa-
tient presents gynoid habitus, abdominal fat, pseudogy-
necomastia (presence of only adipose tissue), hypoplastic
genitalia with microtestes (volume of 2 ml), generalized
hypotonia, genus valgus, pes planus, short toes, café au
lait spot on the left shoulder and in the right lumbar re-
gion. Facial features (Fig. 2) are characterized by: macro-
cephaly, broad forehead, prominent nose root and
coarse nasal pyramid, anteverted nares, white tuft of hair
on the top of his head (Fig. 3).
The mother of the boy presents some atypical char-
acteristics, such as coarse facial features, prominent
frontal bossing, big hands and progressive hearing im-




DNA was extracted from whole blood of the patient
by standard procedures. Array Comparative Genomic
Hybridization (array-CGH) was performed using the
Cytochip ISCA 4x180K (BlueGnome) containing 181,873
oligonucleotide probes (BlueGnome Ldt, Cambridge, UK)
with a mean resolution of 16.30 Kb (25 Kb resolution on
the backbone, 3.4 Kb resolution on genes). The CytoChip
ISCA arrays are designed to investigate constitutional dis-
orders through a combination of increased probe density
in regions or genes associated with known constitutional
disorders and regular spacing of probes on the genomic
backbone, with no known disease association. Data
analysis was performed using InnoScan 710 Microarray
Scanner (Innopsys Inc. Chicago IL, USA) and Bluefuse
software (BlueGnome Ldt, Cambridge, UK). Copy number
variations (CNVs) reported in the Database of Genomic
Variants http://projects.tcag.ca/variation/and in in-house
databases of benign CNVs were excluded from further
analysis. Genomic positions refer to the Human Genome
February 2009 assembly (GRCh37/hg19).
Sequencing
The PROP1 and GJB2 genes were screened for the pres-
ence of causative mutations by direct sequencing. Briefly
genomic DNA was amplified by polymerase chain reac-
tion (PCR) using primers designed to specifically amplify
the coding regions and the intron/exon boundaries of
each gene. PCR conditions and primer sequences are
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available upon request. The PCR products were visual-
ized on a 2 % agarose gel and purified using ExoSAP-IT
enzymatic PCR clean up system (Affimetrix, Santa Clara,
CA). The purified products were then sequenced with
the Big Dye Terminator kit (Applied Biosystems, Foster
City, CA) and the automatic sequencer ABI PRISM 3100
Genetic Analyzer (Applied Biosystems, Foster City, CA).
Database search
We performed a search in DECIPHER database (https://
decipher.sanger.ac.uk/) and ISCA (https://iscaconsortium.
org/) in order to identify cases of patients carrying similar
deletions.
Results
At the age of 18 months, the patient was tested for the
presence of causative mutations in the gene encoding
connexin 26 (GJB2), as he manifested bilateral neurosen-
sorial hearing loss. No mutation associated with hearing
impairment was identified in this gene.
The array-CGH analysis, performed at the age of 13 years,
revealed the presence of an interstitial deletion at Xq21.1
(77.456.818x1,77.489.632-83.255.802x0,83.287.869x1), of
approximately 5.8 Mb (Fig. 4). The same deletion was
present at the heterozygous state in the mother.
Fig. 1 Morphological appearance of the patient at 15 years of age.
Gynoid habitus, abdominal fat, pseudogynecomastia (presence of
only adipose tissue), hypoplastic genitalia with microtestes (volume
of 2 ml), generalized hypotonia, genus valgus, pes planus, short toes
Fig. 2 Facial features of the patient. Patient showing facial
characteristics, including macrocephaly, broad forehead, prominent
nose root and coarse nasal pyramid, anteverted nares, short
palpebral fissures, large and prominent ears
Fig. 3 White tuft of hair on the top of the head
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A paternal inherited deletion on chromosome 22q11.2
of about 105 kb (18.894.864x2, 18.905.139-19.010.478x1,
1.190.35352x2) was also identified, included within the
3 Mb deletion of the DiGeorge syndrome. However, it is
likely a benign CNV as it is present in the Database of
Genomic Variants (http://dgv.tcag.ca/dgv).
The Xq21.1 deleted region was examined using the
Human resource websites (http://www.ncbi.nlm.nih.gov/
projects/genome/guide/human) at NCBI and the Archive
EnsEMBL (http://www.ensembl.org/info/website/archives/
index). This region contains 14 genes, some of them with
a known function (Table 1). Among these, three genes
(TBX22, BRW3 and POU3F4) have been previously re-
ported mutated in well defined disorders, thus facilitating
the phenotype-genotype correlation in our patient (Table 1).
However, none of the genes included in the deletion have
been previously correlated to the pituitary hormone defi-
ciencies observed in our patient. The PROP1 gene was thus
sequenced in order to detect a gene defect elsewhere that
could explain the GH and gonadotropin deficiency, but no
mutation was identified.
Discussion
We report a maternally inherited deletion of approximately
5.8 Mb at Xq21.1, in a male subject with developmental
delay, dysmorphic facial features, cleft palate, intellectual
disability, short stature and hearing loss. The deleted region
includes 14 OMIM genes: CYSLTR1, ZCCHC5, LPAR4,
P2RY10, GPR174, ITM2A, TBX22, BRWD3, HMGN5,
SH3BGRL, HMGN5, SH3BGRL, POU3F4, CYLC1 (Fig. 4
and Table 1). Among these, TBX22, BRWD3 and POU3F4
well explain some of the clinical features of this patient.
Fig. 4 Xq21.1 Deletion. a Graphic representation of part of Xq (corresponding to the region included in the dotted box) with protein coding
genes included in this region. The deletion at Xq21.1 detected in our patient (ChrX:77.456.818x1,77.489.632-83.255.802x0,83.287.869x1) is
represented by a red rectangle above the boxed region. b Schematic representation of the Xq21.1 deleted region (in red) in our patient and
other deletions reported in the Decipher and ISCA database in male patients (in black) and female patients (in grey). The ID of each patient is
reported. The clinical features of the patients are reported in parentheses below the corresponding deletion as described in Decipher (https://
decipher.sanger.ac.uk/) and ISCA (https://iscaconsortium.org/)
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Mutations in the TBX22 gene are a well established
cause of X-linked cleft palate with ankyloglossia as well
as contributing to the prevalence of isolated cleft palate
[5]. More rarely, other craniofacial anomalies including
cleft lip and hypodontia have also been related to TBX22
variants [6]. The phenotypic spectrum of subjects bear-
ing TBX22 mutations can vary, even within the same
family, from asymptomatic females to males or females
with a bifid uvula, a cleft of the soft palate, or a complete
cleft of the hard and soft secondary palate, along with
ankyloglossia [7].
Genetic hearing loss has an extremely varied etiology,
with a plethora of genes involved in the autosomal and
X-linked forms with overlapping phenotypes [8]. Among
the main genetic defects, mutations within connexin 26
(GJB2) and connexin 30 (GJB6) are usually associated
with severe to profound sensorineural deafness. Our
patient had been screened for the presence of muta-
tions in GJB2 before performing array-CGH, and was
negative. The deafness causative gene is undoubtedly
POU3F4, which causes the X-linked neurosensorial
deafness DFN3. This defect is associated with either
POU3F4 point mutations or small deletions in a region
located at 900 Kb upstream of the gene and disturbing
a regulatory element [9]. Male patients show a well
characterized phenotype with both stapes fixation and
progressive mixed hearing loss [10, 11]. Hearing loss
was also observed in the mother of our patient as well
as in about 40 % of the POU3F4 mutation carrier fe-
males. Carrier females usually exhibit a postlingual on-
set of the hearing impairment that progresses over time
[12] with a variable expressivity attributable to varia-
tions in the degree of skewing of X inactivation.
Loss of function mutations affecting BRWD3 are associ-
ated with a phenotype including mild to moderate intellec-
tual disability, macrocephaly, dysmorphic facial features,
skeletal signs and behavioral disturbance [13, 14]. Among
these alterations, a partial deletion encompassing 74 Kb
and including the 30 last exons of the BRWD3 gene was
reported in a male with high forehead, deep-set eyes,
hypertelorism, short palpebral fissures, anteverted nares,
downturned corners of the mouth, pointed chin, and skel-
etal anomalies. This phenotype is similar to that of the pa-
tient presented here: macrocephaly, dysmorphic facial
features including prominent forehead and abnormal ears,
behavioral disturbance, skeletal symptoms like pes planus,
and cubitus valgus. These findings strongly suggest that
the lack of BRWD3 causes intellectual disability, macro-
cephaly and possibly the skeletal symptoms (pes planus
and cubitus valgus) observed in our patient. It has been
demonstrated that BRWD3 plays a crucial role in ubiquiti-
nation, as part of the ubiquitin/proteasome system. In
Drosophila, BRWD3 belongs to the CUL4-ROC1-DDB1
E3 ligase complex in which it acts as a CULLIN (CUL)4-
associated factor that mediates light-dependent binding of
CRY (Cryptochrome, a circadian photoreceptor) to the
complex, inducing the ubiquitination of dCRY and its
light-induced degradation [15]. The ubiquitin-proteasome
system plays a crucial role in brain development and is a
critical regulator of the synaptic plasticity and long-term
memory formation [16]. Intriguingly, in humans muta-
tions of the CUL4B, which encode a ubiquitin 3 ligase
Table 1 Protein encoding genes with a known function included in the Xq21.1 deletion
Gene Protein Protein function Disease
CYSLTR1 Cysteinyl leukotriene receptor 1 Mediation of bronchoconstriction via activation of a
phosphatidylinositol-calcium second messenger system
None
ZCCHC5 Zinc finger, CCHC domain
containing 5
Member of a family of gag-related retrotransposon genes None
LPAR4 Lysophosphatidic acid receptor 4 Monocytic differentiation None
P2RY10 Purinergic receptor P2Y,
G-protein coupled, 10
Stimulation of diacylglyceride-dependent protein kinases None
GPR174 G protein-coupled receptor 174 Lysophosphatidylserine receptor involved in intracellular
cAMP increase
None
ITM2A Integral membrane protein 2A Chondrogenesis None
TBX22 T-box 22 Palatogenesis Cleft palate with ankyloglossia
BRWD3 Bromodomain and WD repeat
domain containing 3
Chromatin-modification Intellectual disability X-linked
with macrocephaly
HMGN5 High mobility group nucleosome
binding domain 5
Nucleosomal binding and transcriptional activation None
SH3BGRL SH3 domain binding glutamate-
rich protein like
Signal transduction None
POU3F4 POU class 3 homeobox 4 Inner ear development Non-syndromic hearing loss
CYLC1 Cylicin, basic protein of sperm
head cytoskeleton 1
Spermatid differentiation None
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subunit cause an X-linked syndrome characterized by
intellectual impairment, macrocephaly, central obesity,
hypogonadism, pes cavus and tremor [17], a phenotype
that largely overlaps with that observed in patients carry-
ing BRWD3 mutations/deletions, including the present
case. As both BRWD3 and CUL4B are part of the same
complex it is likely that alterations of BRWD3 influence
the ubiquitin-proteasome system similarly to other intel-
lectual disability syndromes, whose prototype is repre-
sented by the Angelman Syndrome which is caused by
mutations of the ubiquitin ligase-encoding UBE3A gene
(MIM 105830).
The search in the Decipher and ISCA databases for
similar size deletions at Xq21.1 led to the identification of
six deletions in males with syndromic intellectual disability
and developmental delay (DECIPHER 287069,253735,
257570,292180 and ISCA nsv533989, nsv530231, Fig. 4)
and in one patient with no further phenotype details
(DECIPHER 283100, Fig. 4) but none of these exactly
corresponds to that of our patient. However, among
those observed in female patients, there are two dele-
tions (DECIPHER 262726 and 265126, Fig. 4) that com-
pletely cover that of our patient. The milder associated
phenotype includes broad nasal tip, skeletal defects,
speech delay, and cleft palate, which are also features of
the present patient.
Other remarkable clinical signs of our patient are short
stature and multiple pituitary hormone deficiency. The
presence of mutations in PROP1, the most common
genetic cause of combined pituitary hormone deficiency
(CPHD) associated with short stature [18], was excluded.
It is interesting that the deletion partially overlaps with
regions duplicated in patients with multiple congenital
anomalies, developmental delay, GH deficiency and short
stature [19–21]. This suggests that Xq21.1 might contain
either a protein coding gene or a regulatory element in-
volved in pituitary hormone secretion. Within the 5.8 Mb
region there is no evidence for a protein coding gene dir-
ectly involved in pituitary functioning. However, ITM2A,
included in the deletion, might be related to the severe
short stature as it encodes an integral transmembrane pro-
tein involved in early cartilage development [22]. It has
been suggested that the expression of ITM2A influences
the chondrogenic differentiation potential of mesenchymal
stem cells in vitro [23]. It might be hypothesized that the
absence of ITM2A greatly influences the cartilage devel-
opment with a possible impact on postnatal growth.
Conclusions
In conclusion, a detailed comparison of the clinical charac-
teristics and the function of the genes included in the
Xq21.1 delete region confirm the causative role of this re-
arrangement in our patient. Moreover, the presence of a
gene involved in cartilage differentiation suggests that
ITM2A might be responsible for growth impairment.
Consent
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